Redefining the Standard of Care in High-Risk Resected SCCHN: Insights from the GORTEC 2018-01 NIVOPOST-OP Trial

Highlights

• The GORTEC 2018-01 NIVOPOST-OP trial is the first Phase 3 study to demonstrate a statistically significant disease-free survival (DFS) benefit by adding a PD-1 inhibitor to adjuvant cisplatin-based chemoradiotherapy (CRT) in high-risk resected SCCHN.
• The addition of nivolumab resulted in a 24% reduction in the risk of disease recurrence or death (Hazard Ratio [HR] 0.76), with the benefit observed regardless of PD-L1 expression levels.
• While grade 4 treatment-related adverse events (TRAEs) increased (10% vs 5%), the overall safety profile was manageable, with no increase in treatment-related mortality.
• These findings challenge the 20-year status quo established by the RTOG 9501 and EORTC 22931 trials, positioning nivolumab plus CRT as a new postoperative standard for high-risk patients.

Background

For two decades, the standard of care for patients with locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) who undergo macroscopic complete resection but exhibit high-risk pathological features has been adjuvant cisplatin-based chemoradiotherapy. This standard was established in 2004 by the landmark RTOG 9501 and EORTC 22931 trials, which identified extracapsular nodal extension (ENE) and microscopically positive surgical margins (R1) as the primary indicators for intensified postoperative therapy. Despite this aggressive approach, approximately 50% of high-risk patients experience disease relapse within five years, often with distant metastases or unresectable local recurrence.

The advent of immune checkpoint inhibitors, particularly programmed death 1 (PD-1) blockers, has transformed the management of recurrent/metastatic SCCHN. However, translating these gains into the curative-intent setting (definitive or adjuvant) has proven challenging. Previous trials in the definitive (non-surgical) setting, such as JAVELIN Head and Neck 100 (avelumab) and KEYNOTE-412 (pembrolizumab), failed to meet their primary endpoints. The GORTEC 2018-01 NIVOPOST-OP trial was designed to address this unmet need in the postoperative high-risk surgical population.

Key Content

Mechanistic Rationale for Triple Combination Therapy

The synergy between radiotherapy, cisplatin, and PD-1 blockade forms the biological foundation of NIVOPOST-OP. Radiotherapy induces immunogenic cell death, releasing tumor-associated antigens and Damage-Associated Molecular Patterns (DAMPs), which enhance dendritic cell maturation and T-cell priming. Concurrently, radiation upregulates PD-L1 expression on tumor cells, potentially creating an immunosuppressive microenvironment that nivolumab can reverse. Cisplatin further augments this by increasing MHC class I expression and depleting immunosuppressive myeloid-derived suppressor cells (MDSCs). In the adjuvant setting, where the macroscopic tumor burden has been removed, this combination aims to eradicate micrometastatic disease more effectively than CRT alone.

NIVOPOST-OP Trial Design and Patient Selection

This multicenter, open-label, Phase 3 trial (NCT03576417) enrolled 680 patients across 82 sites in Europe. A key strength of the study was its rigorous definition of “high-risk” features, including:

• Nodal extracapsular extension (ENE).
• Microscopically positive margins (R1).
• Four or more cervical nodal involvements (without ENE).
• Multiple perineural invasions.

Patients were randomized 1:1 to either the control arm (Standard CRT: 66 Gy radiotherapy plus three cycles of cisplatin 100 mg/m²) or the experimental arm (Nivolumab + CRT). The nivolumab regimen was comprehensive, involving a lead-in dose (240 mg), a concomitant phase (360 mg every 3 weeks during CRT), and an adjuvant phase (480 mg every 4 weeks for six cycles).

Efficacy Outcomes: A Shift in the Survival Curve

At a median follow-up of 30.3 months, the primary endpoint of investigator-assessed DFS was met. The nivolumab-containing arm demonstrated a significantly superior DFS compared to the standard CRT arm (HR 0.76; 95% CI 0.60-0.98; p=0.034). This efficacy signal is particularly noteworthy because it remained consistent across various subgroups. Notably, the benefit did not appear to be restricted by PD-L1 expression status, a finding that contrasts with the recurrent/metastatic setting where PD-L1 (Combined Positive Score ≥1 or ≥20) is a critical predictor of response.

Safety and Tolerability Analysis

The intensification of therapy inevitably led to increased toxicity. Grade 4 treatment-related adverse events occurred in 10% of patients in the nivolumab arm compared to 5% in the control arm. However, the rate of treatment-related deaths remained low and identical in both groups (two participants per arm). Common immune-related adverse events associated with nivolumab were consistent with its known profile, including hypothyroidism, skin toxicities, and colitis. Importantly, the addition of nivolumab did not significantly compromise the delivery of the planned radiotherapy dose or the cumulative cisplatin dose, suggesting that the triple combination is feasible in a high-volume clinical setting.

Expert Commentary

The NIVOPOST-OP results represent a significant milestone in head and neck oncology. After numerous negative Phase 3 trials in the definitive setting, the success of this adjuvant trial suggests that the timing of immunotherapy may be crucial. Removing the primary tumor mass and its associated profoundly immunosuppressive microenvironment might allow the immune system to respond more robustly to the PD-1 blockade during and after chemoradiotherapy.

However, several nuances require critical analysis. First, the “high-risk” definition in this trial was broader than the classic EORTC/RTOG criteria (which focused primarily on ENE and R1). The inclusion of patients with ≥4 nodes or multiple perineural invasions reflects a modern understanding of surgical risk but may complicate comparisons with older datasets. Second, the open-label design, while common in radiotherapy trials, introduces potential bias in investigator-assessed DFS. Future publication of overall survival (OS) data and independent central review will be vital to confirm the magnitude of the benefit.

Another point of discussion is the duration of adjuvant nivolumab. The trial utilized six cycles of maintenance therapy. Whether this is the optimal duration—or if even longer maintenance could further improve outcomes—remains an open question. Furthermore, the lack of a PD-L1 correlation suggests that in the context of DNA-damaging agents like radiation and cisplatin, the baseline PD-L1 status might be a less reliable biomarker than in the monotherapy setting.

Conclusion

The GORTEC 2018-01 NIVOPOST-OP trial provides high-level evidence that adding nivolumab to postoperative cisplatin and radiotherapy significantly improves DFS for patients with high-risk LA-SCCHN. While clinicians must remain vigilant regarding the increased risk of grade 4 toxicities, the survival benefit and manageable safety profile support the integration of nivolumab into the adjuvant treatment paradigm. Future research should focus on identifying molecular biomarkers beyond PD-L1 to further refine patient selection and exploring the cost-effectiveness of this new standard of care in global health systems.

References

• Bourhis J, et al. Nivolumab added to cisplatin and radiotherapy versus cisplatin and radiotherapy alone after surgery for people with squamous cell carcinoma of the head and neck at a high risk of relapse (GORTEC 2018-01 NIVOPOST-OP): a randomised, open-label, phase 3 trial. Lancet. 2026;407(10526):363-374. PMID: 41448222.
• Bernier J, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350(19):1945-1952. PMID: 15128894.
• Cooper JS, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004;350(19):1937-1944. PMID: 15128893.
• Machiels JP, et al. Pembrolizumab given concomitantly with chemoradiotherapy and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412. Lancet Oncol. 2024. (Reference for definitive setting comparison).